Current news and events

New insights into the molecular mechanism underlying a human developmental disorder published in Cell Reports

Kari-Anne M Frikstad (first author) and Sebastian Patzke (lead author). Photo: Terje Heiestad

In a recent publication in the journal Cell Reports, Kari-Anne M Frikstad, in team with six international collaborators and her co-workers in Sebastian Patzke's project group at the Institute for Cancer Research, provides new insights on how cells build a functional antenna for sensation of a key developmental signaling pathway required for normal brain development.  

Yan Zhen identifies mechanism of autophagosome closure

Yan Zhen

In a recent paper in the journal Autophagy, Dr. Yan Zhen and her co-workers in Harald Stenmark's group at Institute for Cancer Research and Centre for Cancer Cell Reprogramming (CanCell) show a mechanism for how autophagosomes are sealed, a crucial step in autophagy.

Jan Terje Andersen head of hiv research program receiving 19 mill NOK

Jan Terje Andersen

A consortium of University of Oslo, The International AIDS Vaccine Initiative (IAVI) and the Translational Health Science and Technology Institute (THSTI) has been granted 19.09 MNOK (about U.S. $2.2M) for a period of three years from the Research Council of Norway through the GLOBVAC (Global Health Vaccination and Research) program for the development of broadly neutralizing antibodies as HIV prevention products.

Announcement from Helse Sør-Øst:Call for applications for research-based innovation

Funding of research-based innovation in Helse Sør-Øst is intended to provide financial opportunities for good ideas that have been developed through research activities at the hospitals and private institutions in the region. The ideas must be based on research results with the potential for commercialisation and/or benefit for society. 

Application deadline is Thursday, September 5th 2019, 16:00.

Funding of ideas and inventions in this context involves financing an innovation process, that is to say that the innovation funds will be used to support activities that are linked to defined milestones in the innovation process and which ensure that the development of the idea is continued towards implementation.

Announcement from Helse Sør-Øst:Call for applications for health research

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF) hereby announces a call for applications for health research in this region. The total funding available for this call is approximately 130 million Norwegian kroner.

Application deadline is Thursday, September 5th 2019, 16:00.

The following research categories are available for funding of projects starting in 2020:
PhD fellowships, Postdoctoral fellowships, Career fellowships, Support for clinical research projects, Open project support

Marte Sneeggen identifies new mechanism how a tumor suppressor prevents metastasis

Marte Sneeggen
First author

In a recent article in Nature Communications, published online on the 28thof June, 2019, PhD student Marte Sneeggen and her coworkers at the Institute for Cancer Research and the Center for Cancer Cell Reprogramming (CanCell) identify a new mechanism how the tumor suppressor WDFY2 prevents metastasis by controlling recycling of the matrix metalloproteinase MT1-MMP

One of the most serious complications of cancer is the ability of tumors to form metastases. In most cases, the primary tumor can be treated, whereas metastasis is still the major cause of cancer mortality.

UiO:Life Science funds convergence environment on proton therapy research

Eirik Malinen (top left), Åslaug Helland, Randi Syluåsen and Heidi Lyng

The project Protons contra cancer (PROCCA) was selected as one out of eight new convergence environments that receive funding from UiO: Life Science this year. The convergence environment consists of interdisciplinary research groups that address major challenges within health and environment. The PROCCA consortium intends to create an excellent platform for collaborative efforts in proton therapy research in Oslo, and consists of research groups from several departments at UiO and OUS.

The consortium is headed by Eirik Malinen, Department of Physics, UiO, and Department of Medical Physics, OUS. At Institute for Cancer Research, Åslaug Helland, Department of Genetics, is one of the principal investigators, and Randi Syljuåsen and Heidi Lyng at Department of Radiation Biology are collaborators.

Three new strategic research areas appointed by Oslo University Hospital

From left: Johannes Hov, Ragnhild A. Lothe and Karl-Johan Malmberg

In competition between 30 very good applicants, the hospital's external Scientific Advisory Board has selected three new strategic research areas for Oslo University Hospital.

Personalized treatment is central to all three areas; intestinal microflora treatment as part of personalized medicine, ex vivo drug testing as a basis for personalized treatment of intestinal cancer and cell-based immunotherapy against cancer.

The initiatives are led by Johannes Espolin Roksund Hov, Ragnhild A. Lothe and Karl-Johan Malmberg.

The Scientific Adisory Board members were impressed by the high quality of the applications in general and identified several innovative research approaches.

Perspective article in Nature Communications by Skotland and Sandvig: Importance of studying lipid species, not only lipid classes

Each cell contains several thousand unique lipid molecules. There are several lipid classes based on lipids having various head groups (e.g. choline, ethanolamine, serine or inositol), whereas differences in hydrophobic fatty acyl chains give rise to a diversity of species within each class. By using mass spectrometry analysis it is now possible to quantify approx. 1000 lipid species in one sample.

More news from the archive